What isPEG-MGFFDA Status, Evidence and Risks (2026)
Be first to know.Email the day PEG-MGF's FDA or HHS status changes.
Updates only. Doesn't reserve treatment. Unsubscribe anytime. Privacy
Off FDA's Category 2 safety-risk list since Apr 2026. Review pending. Not on the 503A bulks list. Not approved by FDA for any use. FDA found no human exposure data for PEG-MGF by any route. Plain MGF sits in 503A Category 3. Banned in sport by WADA at all times. Sources: FDA, Category 2 page current as of Apr 22, 2026 1, 503A pages current as of May 14, 2026 2,3; WADA 2026 Prohibited List 4.
Part of the Sommar Peptide Guide. PEG-MGF gets sold as a muscle peptide. FDA says it has no data on what it does in people. Here is what is on file.
What PEG-MGF is
Start with MGF, short for mechano growth factor. It is one version of IGF-1, a growth signal, made when the IGF-1 gene is spliced a certain way. In people that version is called IGF-1Ec 5. Muscle that is stretched or overloaded makes more of it 5. Researchers first described it in 1996 as a response to mechanical stress 6.
The MGF sold online is usually a lab-made 24-amino-acid piece of it 6. MGF breaks down fast in the body 5,7, so makers change it to last longer. One change is PEGylation, the "PEG" in the name.
PEG is polyethylene glycol, a polymer chain attached to a drug. On approved protein drugs, PEG keeps them circulating longer and can shield them from the immune system 8. PEG-MGF is MGF with PEG attached.
| PEG-MGF | Plain MGF | |
|---|---|---|
| What it is | MGF with a PEG chain attached 7 | A 24-amino-acid piece of IGF-1Ec, or a longer form 6 |
| FDA list for pharmacies (503A) | Off Category 2 since Apr 2026, review pending 1,9 | Category 3, nominated without adequate support 3 |
| Human evidence | FDA found none, by any route 1 | Efficacy in people "not proven" 5 |
| WADA | Banned at all times 4 | Banned at all times 4 |
Where FDA stands
- Apr 15, 2026: FDA said it would remove 12 peptides from Category 2 "within seven calendar days," because their nominators withdrew them. PEG-MGF was one 9.
- Apr 22, 2026: FDA's page lists PEG-MGF in its withdrawn table, with its safety concerns still attached 1.
- May 14, 2026: not on the 503A bulks list 2. Plain MGF sits in Category 3, "Bulk Drug Substances Nominated Without Adequate Support" 3. FDA may still take enforcement action on Category 3 substances under its general policies 2.
- Before end of Feb 2027: a second FDA advisory committee meeting is expected for PEG-MGF and four other peptides. FDA has not set a date 10. Any vote would be advice only.
Leaving Category 2 approved nothing. PEG-MGF is not approved by FDA for any use. Are Peptides Legal? explains why.
Not in the HHS policy. On Oct 28, 2026, HHS filed an interim enforcement discretion policy covering six peptides: BPC-157, TB-500, MOTS-c, epitalon, semax and KPV 11. PEG-MGF is not one of them and keeps its prior status, as of Oct 29, 2026. The FDA Peptide Tracker logs every change.
What the research shows
For PEG-MGF in people, nothing. FDA "has not identified any human exposure data" for PEG-MGF given by any route 1.
The muscle claims borrow from studies of plain MGF in cells and animals:
- Muscle cells. The synthetic MGF peptide pushed muscle stem cells (satellite cells) to multiply in lab studies, including cells from elderly donors 5.
- Heart, in sheep. After a heart attack, MGF delivered into a heart artery improved heart function more than IGF-1 did 5.
- Ligament, in rabbits. A 2022 study reported faster ACL repair in rabbits and better movement of injured human ligament cells in a dish 12.
None of that is PEG-MGF, and none of it is a human trial.
The researchers who study MGF are careful about it. A 2012 review said "its efficacy in man is not proven." It also said the body's own working form of the peptide "has not been confirmed" 5.
Side effects and FDA's concerns
Side effects in people are unknown. No one has published the data.
FDA's stated concerns, from its Category 2 page 1:
- Immune reactions. PEG-MGF "may pose significant risk for immunogenicity" for certain routes.
- Impurities. Complexities with peptide-related impurities and with characterizing the substance.
- No human data. FDA "lacks important information regarding any safety issues," including "whether it would cause harm if administered to humans."
The open questions:
| Question | What's on file |
|---|---|
| Cancer | A 2020 review says "a clearly mitogenic role in tumor biology is attributed" to IGF-1Ec, based mainly on cancer cell studies. In one study, the synthetic peptide made a breast cancer cell line grow faster in a dish 13. That is cell work, not proof of harm in people. |
| Black-market versions | MGF analogues sold illegally may have "unknown properties and potentially serious side effects," per the 2012 review 5. |
| What PEG changes | PEG can keep a drug in the body longer 8. How long PEG-MGF lasts in a person has never been measured, as far as FDA found 1. |
Why it's sold online anyway
MGF "has become an important component of the readily available anabolic and doping products," the 2012 review said 5. In 2014, doping scientists found a "full-length" MGF product in illicit channels and built a test for it 6.
Most PEG-MGF online carries a "research use only" label. That label is the seller saying the product is not made for people. It skips a prescriber, a licensed pharmacy and any quality check for human use. Prescription vs Research Peptides has more.
If you compete, WADA's 2026 list bans mechano growth factors by name, in and out of competition 4. MGF has been prohibited since 2005 6.
Other peptides on this shelf: TB-500, which the Oct 28 HHS policy does cover, and LL-37, waiting on the same panel review as PEG-MGF.
Asked a lot.
The sources.
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026). Read it
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026). Read it
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026). Read it
- World Anti-Doping Agency. The Prohibited List (2026), S2.3 Growth Factors and Growth Factor Modulators. Read it
- Zabłocka B, Goldspink PH, Goldspink G, Górecki DC. Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol. 2012;3:131. doi:10.3389/fendo.2012.00131. Read it
- Thevis M, Thomas A, Geyer H, Schänzer W. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls. Growth Horm IGF Res. 2014;24(6):276-281. Read it
- Wikipedia. Mechano growth factor (second source only, for chemistry). Read it
- Alconcel SNS, Baas AS, Maynard HD. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym Chem. 2011. doi:10.1039/c1py00034a. Read it
- Frier Levitt. FDA Peptides "Do Not Compound" List Update (Apr 16, 2026). Read it
- Holland & Knight. Peptides at a Crossroads: What Wellness Providers Need to Know (Oct 16, 2026). Read it
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496, FR Doc 2026-22192 (filed for public inspection Oct 28, 2026; scheduled to publish in the Federal Register Oct 30, 2026). Read it
- Sha Y, Zhang B, Chen L, Hong H, Chi Q. Mechano Growth Factor Accelerates ACL Repair and Improves Cell Mobility of Mechanically Injured Human ACL Fibroblasts by Targeting Rac1-PAK1/2 and RhoA-ROCK1 Pathways. Int J Mol Sci. 2022;23(8):4331. doi:10.3390/ijms23084331. Read it
- Kasprzak A, Szaflarski W. Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors. Int J Mol Sci. 2020;21(19):6995. doi:10.3390/ijms21196995. Read it
Be first to know.
Get an email the day PEG-MGF's FDA or HHS status changes. Updates are for education only. Joining doesn't reserve treatment.
Email only. Please don't share health details here. Privacy Policy